First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens

BACKGROUND: Sub-Saharan African countries are transitioning to dolutegravir-based regimens, even for patients with extensive previous drug exposure, including first-generation integrase strand-transfer inhibitors (INSTI) such as raltegravir. Such exposure might have implications on cross-resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Fokam, Joseph, Takou, Desire, Semengue, Ezechiel Ngoufack Jagni, Teto, Georges, Beloumou, Grace, Dambaya, Beatrice, Santoro, Maria-Mercedes, Mossiang, Leonella, Billong, Serge Clotaire, Cham, Fatim, Sosso, Samuel Martin, Temgoua, Edith Saounde, Nanfack, Aubin Joseph, Moudourou, Sylvie, Kamgaing, Nelly, Kamgaing, Rachel, Ngako Pamen, Joelle Nounouce, Etame, Mireille Mpoudi Ngole, Bissek, Anne-Cecile Z.-K., Elat, Jean-Bosco N., Moussi, Emmanuel Eben, Colizzi, Vittorio, Perno, Carlo-Federico, Ndjolo, Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449072/
https://www.ncbi.nlm.nih.gov/pubmed/32843050
http://dx.doi.org/10.1186/s13756-020-00799-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449072/
https://www.ncbi.nlm.nih.gov/pubmed/32843050
http://dx.doi.org/10.1186/s13756-020-00799-2

Ejemplares similares